Adjust to new costs of 137 anti-cancer medication or face motion, says regulator

The Nationwide Pharmaceutical Pricing Authority (NPPA) has warned of penal motion in opposition to these failing to adjust to the revised costs of 137 non-scheduled anti-cancer medication

The authority, which capabilities beneath the Division of Prescribed drugs, has requested State drug controllers (SDCs) to strictly monitor the costs and submit their motion taken studies by November 16, in accordance with an official launch on Friday (November 13, 2026).

The revised costs for the 137 anti-cancer medication got here into impact on November 9, 2026, following a gazette order issued on October 17, 2026. The order capped the commerce margin on these medicines at 30%.

Primarily based on submissions obtained from pharmaceutical firms as much as November 11, the newest revised tariffs have been uploaded on the NPPA web site in addition to the Pharma Sahi Daam app and portal, the Chemical compounds and Fertilizers Ministry mentioned.

All producers, stockists, sellers, retailers, hospitals, and medical establishments have been directed to adjust to the revised costs and prominently show the up to date tariffs at their premises and on their web sites.

The SDCs have been instructed to strictly monitor compliance throughout the provision chain and healthcare amenities to make sure that the advantages of the revised most retail costs (MRPs) are handed on to sufferers.

Any violation of the directive could entice overcharging proceedings beneath the provisions of the DPCO, 2013, the discharge famous.

Complaints concerning overcharging, scarcity, or non-availability of medicines might be reported by means of the Pharma Sahi Daam app or portal, the NPPA helpline (1800-111-255), or through electronic mail at monitoring-nppa@gov.in, it added.